Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit

Advances in the management of hematologic malignancies and solid tumors have given rise to diverse modalities to treat cancer other than cytotoxic chemotherapy, including targeted therapies, immunotherapies, and cellular therapies. Currently, there are over 175 FDA-approved antineoplastic agents in...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivera, Melvin J., Do, Bryan, Bryan, Jeffrey C., Shigle, Terri Lynn, Patel, Rina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121489/
http://dx.doi.org/10.1007/978-3-319-74588-6_21
_version_ 1783515213658587136
author Rivera, Melvin J.
Do, Bryan
Bryan, Jeffrey C.
Shigle, Terri Lynn
Patel, Rina
author_facet Rivera, Melvin J.
Do, Bryan
Bryan, Jeffrey C.
Shigle, Terri Lynn
Patel, Rina
author_sort Rivera, Melvin J.
collection PubMed
description Advances in the management of hematologic malignancies and solid tumors have given rise to diverse modalities to treat cancer other than cytotoxic chemotherapy, including targeted therapies, immunotherapies, and cellular therapies. Currently, there are over 175 FDA-approved antineoplastic agents in the United States, many with a diverse and profound toxicity profile. Complications of antineoplastic therapy may result in the need for intensive care unit (ICU) admission to provide acute symptom management. Accordingly, ICU providers caring for cancer patients should have a working knowledge of the toxicities and complications associated with antineoplastic therapy.
format Online
Article
Text
id pubmed-7121489
institution National Center for Biotechnology Information
language English
publishDate 2019
record_format MEDLINE/PubMed
spelling pubmed-71214892020-04-06 Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit Rivera, Melvin J. Do, Bryan Bryan, Jeffrey C. Shigle, Terri Lynn Patel, Rina Oncologic Critical Care Article Advances in the management of hematologic malignancies and solid tumors have given rise to diverse modalities to treat cancer other than cytotoxic chemotherapy, including targeted therapies, immunotherapies, and cellular therapies. Currently, there are over 175 FDA-approved antineoplastic agents in the United States, many with a diverse and profound toxicity profile. Complications of antineoplastic therapy may result in the need for intensive care unit (ICU) admission to provide acute symptom management. Accordingly, ICU providers caring for cancer patients should have a working knowledge of the toxicities and complications associated with antineoplastic therapy. 2019-07-09 /pmc/articles/PMC7121489/ http://dx.doi.org/10.1007/978-3-319-74588-6_21 Text en © Springer Nature Switzerland AG 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Rivera, Melvin J.
Do, Bryan
Bryan, Jeffrey C.
Shigle, Terri Lynn
Patel, Rina
Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit
title Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit
title_full Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit
title_fullStr Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit
title_full_unstemmed Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit
title_short Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit
title_sort complications and toxicities associated with cancer therapies in the intensive care unit
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121489/
http://dx.doi.org/10.1007/978-3-319-74588-6_21
work_keys_str_mv AT riveramelvinj complicationsandtoxicitiesassociatedwithcancertherapiesintheintensivecareunit
AT dobryan complicationsandtoxicitiesassociatedwithcancertherapiesintheintensivecareunit
AT bryanjeffreyc complicationsandtoxicitiesassociatedwithcancertherapiesintheintensivecareunit
AT shigleterrilynn complicationsandtoxicitiesassociatedwithcancertherapiesintheintensivecareunit
AT patelrina complicationsandtoxicitiesassociatedwithcancertherapiesintheintensivecareunit

Ejemplares similares